Combination of ibrutinib and chemotherapy produced a durable remission in multiply relapsed diffuse large B-cell lymphoma leg type with mutantMYD88and wildtypeCD79.
Columbia University Medical Center, Center for Lymphoid Malignancies, New York, NY, USA.
Andrew L
AL
Deng
Columbia University Medical Center, Center for Lymphoid Malignancies, New York, NY, USA.|Department of Internal Medicine, Yonsei University, Seoul, Korea.
Yu Ri
YR
Kim
Columbia University Medical Center, Center for Lymphoid Malignancies, New York, NY, USA.
Emily A
EA
Lichtenstein
Columbia University Medical Center, Center for Lymphoid Malignancies, New York, NY, USA.
Owen A
OA
O'Connor
Columbia University Medical Center, Center for Lymphoid Malignancies, New York, NY, USA cd2448@columbia.edu.
Changchun
C
Deng
D000225:Adenine / Q000031:analogs & derivatives; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D051925:CD79 Antigens / Q000235:genetics*; D005260:Female; D006801:Humans; D016130:Immunophenotyping; D016403:Lymphoma, Large B-Cell, Diffuse / Q000175:diagnosis / Q000188:drug therapy* / Q000235:genetics*; D009154:Mutation; D053594:Myeloid Differentiation Factor 88 / Q000235:genetics*; D010880:Piperidines; D000072078:Positron Emission Tomography Computed Tomography; D011720:Pyrazoles / Q000008:administration & dosage; D011743:Pyrimidines / Q000008:administration & dosage; D012008:Recurrence; D019233:Retreatment; D016896:Treatment Outcome
D051925:CD79 Antigens; D053594:Myeloid Differentiation Factor 88; D010880:Piperidines; D011720:Pyrazoles; D011743:Pyrimidines; C551803:ibrutinib; D000225:Adenine